abstract |
Aspects of the present disclosure relate to compounds which have enhanced oral bioavailability. A transition metal complex includes a transition metal coordinated by a macrocycle comprising the pentaaza 15-membered macrocyclic ring corresponding to Formula A and two axial ligands having the formula —OC(O)X 1 . n n n n n n n n n n n n each of the two axial ligands has the formula —OC(═O)X 1 wherein each X 1 is independently substituted or unsubstituted phenyl or —C(—X 2 )(—X 3 )(—X 4 ); n each X 2 is independently substituted or unsubstituted phenyl, or substituted or unsubstituted alkyl; n each X 3 is independently hydrogen, hydroxyl, alkyl, amino, —X 5 C(═O)R 13 where X 5 is NH or O, and R 13 is C 1 -C 18 alkyl, substituted or unsubstituted aryl or C 1 -C 18 aralkyl, or —OR 14 , where R 14 is C 1 -C 18 alkyl, substituted or unsubstituted aryl or C 1 -C 18 aralkyl, or together with X 4 is (═O); and n each X 4 is independently hydrogen or together with X 3 is (═O). |